Treatment-resistant depression (TRD) is prevalent and associated with a substantial psychosocial burden and mortality. There are few prior studies of interventions for TRD in adolescents. This was the largest study to date examining the feasibility, safety, and efficacy of 10-Hz transcranial magnetic stimulation (TMS) for adolescents with TRD. Adolescents with TRD (aged 12–21 years) were enrolled in a randomized, sham-controlled trial of TMS across 13 sites. Treatment resistance was defined as an antidepressant treatment record level of 1 to 4 in a current episode of depression. Intention-to-treat patients (n = 103) included those randomly assigned to active NeuroStar TMS monotherapy (n = 48) or sham TMS (n = 55) for 30 daily treatments over 6 weeks. The primary outcome measure was change in the Hamilton Depression Rating Scale (HAM-D-24) score. After 6 weeks of blinded treatment, improvement in the least-squares mean (SE) HAM-D-24 scores were similar between the active (−11.1 [2.03]) and sham groups (−10.6 [2.00]; P = 0.8; difference [95% CI], − 0.5 [−4.2 to 3.3]). Response rates were 41.7% in the active group and 36.4% in the sham group (P = 0.6). Remission rates were 29.2% in the active group and 29.0% in the sham group (P = 0.95). There were no new tolerability or safety signals in adolescents. Although TMS treatment produced a clinically meaningful change in depressive symptom severity, this did not differ from sham treatment. Future studies should focus on strategies to reduce the placebo response and examine the optimal dosing of TMS for adolescents with TRD.
Subscribe to Journal
Get full journal access for 1 year
only $38.38 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008;299:901–13.
March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807–20.
Strawn JR, Aaronson ST, Elmaadawi AZ, Schrodt GR, Holbert RC, Verdoliva S, et al. Treatment-resistant depression in adolescents: clinical features and measurement of treatment resistance. J Child Adolesc Psychopharmacol 2020;30:261–66.
Strawn JR, Croarkin PE. Commentary: Treatment failure and success: a commentary on defining and treating pediatric treatment-resistant depression - reflections on Dwyer et al. (2020). J Child Psychol Psychiatry 2020;61:333–35.
Emslie GJ, Mayes T, Porta G, Vitiello B, Clarke G, Wagner KD, et al. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry 2010;167:782–91.
Suresh V, Mills JA, Croarkin PE, Strawn JR What next? A Bayesian hierarchical modeling re-examination of treatments for adolescents with selective serotonin reuptake inhibitor-resistant depression. Depress Anxiety. 2020.
Dwyer JB, Stringaris A, Brent DA, Bloch MH. Annual research review: defining and treating pediatric treatment-resistant depression. J Child Psychol Psychiatry 2020;61:312–32.
Vanbronkhorst SB, Roberts DE, Edwards EM, Blankenship K. Diagnosis and use of psychotherapy among children and adolescents prescribed antipsychotics. J Psychiatr Pract 2018;24:323–30.
Voineskos AN, Mulsant BH, Dickie EW, Neufeld NH, Rothschild AJ, Whyte EM, et al. Effects of antipsychotic medication on brain structure in patients with major depressive disorder and psychotic features: neuroimaging findings in the context of a randomized Placebo-controlled clinical trial. JAMA Psychiatry. 2020.
Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry 2013;70:1067–75.
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011;8:114–26.
Hayden JD, Horter L, Parsons T III, Ruble M, Townsend S, Klein CC, et al. Metabolic monitoring rates of youth treated with second-generation antipsychotics in usual care: results of a large US national commercial health plan. J Child Adolesc Psychopharmacol 2020;30:119–22.
Puffer CC, Wall CA, Huxsahl JE, Frye MA. A 20 year practice review of electroconvulsive therapy for adolescents. J Child Adolesc Psychopharmacol 2016;26:632–6.
George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010;67:507–16.
Lefaucheur JP, Andre-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014;125:2150–206.
O’Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007;62:1208–16.
Wall CA, Croarkin PE, Maroney-Smith MJ, Haugen LM, Baruth JM, Frye MA, et al. Magnetic resonance imaging-guided, open-label, high-frequency repetitive transcranial magnetic stimulation for adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2016;26:582–9.
Wall CA, Croarkin PE, Sim LA, Husain MM, Janicak PG, Kozel FA, et al. Adjunctive use of repetitive transcranial magnetic stimulation in depressed adolescents: a prospective, open pilot study. J Clin Psychiatry 2011;72:1263–9.
Donaldson AE, Gordon MS, Melvin GA, Barton DA, Fitzgerald PB. Addressing the needs of adolescents with treatment resistant depressive disorders: a systematic review of rTMS. Brain Stimul 2014;7:7–12.
Krishnan C, Santos L, Peterson MD, Ehinger M. Safety of noninvasive brain stimulation in children and adolescents. Brain Stimul 2015;8:76–87.
Croarkin PE, Rotenberg A. Pediatric neuromodulation comes of age. J Child Adolesc Psychopharmacol 2016;26:578–81.
U.S. Food and Drug Administration. Leveraging existing clinical data for extrapolation to pediatric uses of medical devices. 2016. https://www.fda.gov/media/91889/download. Accessed June 29 2020.
McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M, Taylor SF, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry. 2018;79.
Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997;54:1031–7.
Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 2009;48:721–29.
Walkup JT. Antidepressant efficacy for depression in children and adolescents: industry- and NIMH-funded studies. Am J Psychiatry 2017;174:430–37.
Stevely A, Dimairo M, Todd S, Julious SA, Nicholl J, Hind D, et al. An investigation of the shortcomings of the CONSORT 2010 statement for the eporting of group sequential randomised controlled trials: a methodological systematic review. PLoS One 2015;10:e0141104.
American Psychiatric Association, American Psychiatric Association DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. American Psychiatric Association: Arlington, VA; Washington, D.C.; 2013.
Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278–96.
Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):10–7.
Sheehan DV, Sheehan KH, Shytle RD, Janavs J, Bannon Y, Rogers JE, et al. Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). J Clin Psychiatry 2010;71:313–26.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22–33. quiz 34-57
Rossi S, Hallett M, Rossini PM, Pascual-Leone A. Safety of TMSCG. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009;120:2008–39.
Weintraub S, Dikmen SS, Heaton RK, Tulsky DS, Zelazo PD, Bauer PJ, et al. Cognition assessment using the NIH Toolbox. Neurology 2013;80(11 Suppl 3):S54–64.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–9.
Poznanski EO, Grossman JA, Buchsbaum Y, Banegas M, Freeman L, Gibbons R. Preliminary studies of the reliability and validity of the children’s depression rating scale. J Am Acad Child Psychiatry 1984;23:191–7.
Guy W, National Institute of Mental Health (Rockville Md.). Psychopharmacology Research Branch. Division of Extramural Research Programs. ECDEU assessment manual for psychopharmacology: 1976. Revised. ed. National Institute of Mental Health: Rockville (Md.); 1976.
Bernstein IH, Rush AJ, Trivedi MH, Hughes CW, Macleod L, Witte BP, et al. Psychometric properties of the quick inventory of depressive symptomatology in adolescents. Int J Methods Psychiatr Res 2010;19:185–94.
Nandakumar AL, Vande Voort JL, Nakonezny PA, Orth SS, Romanowicz M, Sonmez AI, et al. Psychometric properties of the patient health questionnaire-9 modified for major depressive disorder in adolescents. J Child Adolesc Psychopharmacol 2019;29:34–40.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266–77.
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429–35.
Kennard BD, Silva SG, Mayes TL, Rohde P, Hughes JL, Vitiello B, et al. Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. Am J Psychiatry 2009;166:337–44.
Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009;166:42–9.
Nakonezny PA, Mayes TL, Byerly MJ, Emslie GJ. Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS). J Psychiatr Res 2015;68:346–53.
Yesavage JA, Fairchild JK, Mi Z, Biswas K, Davis-Karim A, Phibbs CS, et al. Effect of repetitive transcranial magnetic stimulation on treatment-resistant major depression in US veterans: a randomized clinical trial. JAMA Psychiatry 2018;75:884–93.
Dhami P, Knyahnytska Y, Atluri S, Lee J, Courtney DB, Croarkin PE, et al. Feasibility and clinical effects of theta burst stimulation in youth with major depressive disorders: an open-label trial. J Affect Disord 2019;258:66–73.
DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2017;56:1015–25.
Zhang W, Xiao Y, Sun H, Patino LR, Tallman MJ, Weber WA, et al. Discrete patterns of cortical thickness in youth with bipolar disorder differentially predict treatment response to quetiapine but not lithium. Neuropsychopharmacology 2018;43:2256–63.
Croarkin PE, Nakonezny PA, Deng ZD, Romanowicz M, Voort JLV, Camsari DD, et al. High-frequency repetitive TMS for suicidal ideation in adolescents with depression. J Affect Disord 2018;239:282–90.
Lewis CP, Nakonezny PA, Blacker CJ, Vande Voort JL, Port JD, Worrell GA, et al. Cortical inhibitory markers of lifetime suicidal behavior in depressed adolescents. Neuropsychopharmacology 2018;43:1822–31.
Williams NR, Sudheimer KD, Bentzley BS, Pannu J, Stimpson KH, Duvio D, et al. High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. Brain 2018;141:e18.
Eshel N, Leibenluft E. New frontiers in irritability research-from cradle to grave and bench to bedside. JAMA Psychiatry. 2019.
Keren H, O’Callaghan G, Vidal-Ribas P, Buzzell GA, Brotman MA, Leibenluft E, et al. Reward processing in depression: a conceptual and meta-analytic review across fMRI and EEG studies. Am J Psychiatry 2018;175:1111–20.
Mir-Moghtadaei A, Caballero R, Fried P, Fox MD, Lee K, Giacobbe P, et al. Concordance between BeamF3 and MRI-neuronavigated target sites for repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex. Brain Stimul 2015;8:965–73.
Mansouri F, Mir-Moghtadaei A, Niranjan V, Wu JS, Akhmedjanov D, Nuh M, et al. Development and validation of a 3D-printed neuronavigation headset for therapeutic brain stimulation. J Neural Eng 2018;15:046034.
The authors would like to acknowledge the participating clinical trial sites and investigative teams: Dothan Behavioral Medicine, Dothan, Alabama; University of California, Los Angeles, Los Angeles, California; Stanford University, Palo Alto, California; Rocky Mountain TMS, Grand Junction, Colorado; Florida Clinical Practice Association, Inc, Gainesville, Florida; Anchor Neuroscience, Pensacola, Florida; Beacon Medical Group, South Bend, Indiana; Integrative Psychiatry, Louisville, Kentucky; Sheppard Pratt Health System, Baltimore, Maryland; Mayo Clinic, Rochester, Minnesota; University of Cincinnati College of Medicine, Cincinnati, Ohio; The Ohio State University, Columbus, Ohio; and Medical University of South Carolina, Charleston, South Carolina.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Croarkin, P.E., Elmaadawi, A.Z., Aaronson, S.T. et al. Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial. Neuropsychopharmacol. (2020). https://doi.org/10.1038/s41386-020-00829-y